article thumbnail

Osteoboost: FDA-Cleared Wearable Device for Osteopenia Treatment Open for Pre-Orders

HIT Consultant

Recently cleared by the FDA, Osteoboost is clinically proven to significantly slow bone density and strength loss through its patented precision vibration therapy, specifically targeting postmenopausal women with osteopenia.

FDA 98
article thumbnail

The FDA Backdoor to MDMA Rescheduling

Bill of Health

Food and Drug Administration (FDA) for post-traumatic stress disorder (PTSD) means the drug may be rescheduled, which will lead to substantially decreased regulations attached to it. However, in 2016, DEA added some clarity to the “accepted medical use” qualification, saying that FDA approval was one way to achieve this threshold.

FDA 202
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Teal Wand™: The First At-Home Self-Collection Device for Cervical Cancer Screening in the U.S.

HIT Consultant

Food and Drug Administration (FDA) has approved the Teal Wand , marking it as the first and only at-home self-collection device for cervical cancer screening in the United States. The Teal Wand simply offers a different, FDA-approved method for collecting the sample.

FDA 66
article thumbnail

Hims? Hers? It’s Novo Nordisk’s Semaglutide Market Now

Bill of Health

An FDA announcement that semaglutide injection products, the GLP-1 medication in the blockbuster drugs Wegovy and Ozempic, are no longer in shortage. An FDA announcement that semaglutide injection products, the GLP-1 medication in the blockbuster drugs Wegovy and Ozempic, are no longer in shortage.

FDA 130
article thumbnail

Abbott receives FDA clearance for AI-powered heart imaging software

Mobi Health News

Abbott has received clearance from the FDA for its imaging software that uses artificial intelligence to provide doctors a better view of blood flow and blockages in heart vessels.

FDA 132
article thumbnail

Cognoa's FDA-approved autism diagnostic tool now in-network for Highmark members

Fierce Healthcare

Cognoa, maker of the first FDA-approved autism diagnostic tool, announced Highmark has signed on as its first commercial payer partner. | The tool, Canvas Dx, leverages AI to empower doctors to quickly and accurately diagnose developmental risk without bias, the company claims. It is the first FDA-approved autism diagnostic tool.

FDA 130
article thumbnail

National University Hospital testing predictive AI for Alzheimer's diagnosis and more AI briefs

Healthcare It News

It recently invested in Hong Kong-based health technology company Belun, which received the first United States FDA approval for an AI-powered platform for sleep apnoea diagnosis. The ring collects data which is then compiled into a clinical report for doctors who are helping manage their health.

Hospitals 312